https://doi.org/10.4081/hmr.v1i8.296

Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 201
PDF: 327
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

K Bhalla
support@pagepress.org
Histone deacetylase (HDAC) inhibitors (HDIs) are potent inducers of in vitro growth arrest, differentiation and apoptosis of human leukemia and lymphoma cells as well as exert in vivo anti-leukemia and anti-lymphoma effects. The hydroxamic acid (HA) analogue class of HDIs, e.g., LBH589 and LAQ824, have been shown to induce not only the acetylation of the lysine residues of core nucleosomal histones but also of transcription factors and other important proteins. Thus, they should be referred to as protein deacetylases. Together, HA-HDI-induced modifications of proteins mediate the biologic the therapeutic effects, which are currently being investigated through pre-clinical and clinical studies in hematologic malignancies. This review briefly describes the current status of the development of these agents in the therapy of hematologic malignancies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Bhalla, K. (2009). Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.296
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).